Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. University of Alberta, Edmonton, Alberta, Canada

Survival: 27.2 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: Canada
City/State/Province: Edmonton, Alberta
Hospital: University of Alberta
Journal: Link
Date: 1/2015

This phase 3 study involved female metastatic breast cancer patients who were divided into two separate treatment groups. Group A had 759 patients with a median age of 54 years, and group B had 385 patients with a median age of 54 years.

Patients in group A received chemotherapy with docetaxel and biologic therapy with ramucirumab (a monoclonal antibody that blocks the VEGFR-2 protein and interferes with cancer cell growth).

Patients in group B received chemotherapy with docetaxel and a placebo.

This study reported grade 3 or higher fatigue, neutropenia with fever, congestive heart failure, and blood clots. However, treatment-related deaths (grade 5 toxicity) were not specifically mentioned.

The median overall survival rates for groups A and B were 27.3 and 27.2 months, respectively.

This study was supported by Eli Lilly/ImClone Systems, makers of ramucirumab.

Correspondence: Dr. John R. Mackey; email:

E-mail to a Friend Email Physician More Information